Listed

Universal Technical Institute Inc: Form 10-Q for the period ended Mar 31, 2024

Filed with the SEC on May 9, 2024 and accepted by EDGAR at May 9, 2024, 08:42 ET.

Share

Management's discussion and analysis

As filed, 51,968 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

The following discussion and analysis should be read in conjunction with the condensed consolidated financial statements and related notes included in this Quarterly Report on Form 10-Q and those in our 2023 Annual Report on Form 10-K. This discussion contains forward-looking statements that involve risks and uncertainties. Our actual results may differ materially from those anticipated in such forward-looking statements as a result of certain factors, including but not limited to those described under “Risk Factors” in our 2023 Annual Report on Form 10-K and included in Part II, Item 1A of this Quarterly Report on Form 10-Q. See also “Cautionary Note Regarding Forward-Looking Statements” on page ii of this Quarterly Report on Form 10-Q.

Company Overview

Universal Technical Institute, Inc., which together with its subsidiaries is referred to as the “Company,” “we,” “us” or “our,” was founded in 1965 and is a leading workforce solutions provider of transportation, skilled trades and healthcare education programs, whose mission is to serve students, partners, and communities by providing quality education and support services for in-demand careers across a number of highly-skilled fields. We offer the majority of our programs in a blended learning model that combines instructor-facilitated online teaching and demonstrations with hands-on labs.

Universal Technical Institute (“UTI”): UTI operates 16 campuses located in nine states and offers a wide range of degree and non-degree transportation and skilled trades technical training programs under brands such as Universal Technical Institute, Motorcycle Mechanics Institute, Marine Mechanics Institute, NASCAR Technical Institute, and MIAT College of Technology (“MIAT”). UTI also offers manufacturer specific advanced training programs, which include student-paid electives, at our campuses and manufacturer or dealer sponsored training at certain campuses and dedicated training centers. Lastly, UTI provides dealer technician training or instructor staffing services to manufacturers. UTI works closely with multiple original equipment manufacturers and industry brand partners to understand their needs for qualified service professionals.

Concorde Career Colleges (“Concorde”): Concorde operates across 17 campuses in eight states, offering degree, non-degree, and continuing education programs in the allied health, dental, nursing, patient care and diagnostic fields. Concorde believes in preparing students for their health care careers with practical, hands-on experiences including opportunities to learn while providing care to real patients. Prior to graduation, students will complete a number of hours in a clinical setting or externship, depending upon their program of study.

“Corporate” includes corporate related expenses that are not allocated to the UTI or Concorde reportable segments. See Note 19 of the notes to the condensed consolidated financial statements herein for additional details on our segments.

All of our campuses are accredited and are eligible for federal student financial assistance funds under the Higher Education Act of 1965, as amended, commonly referred to as Title IV Programs, which are administered by the U.S. Department of Education. Our programs are also eligible for financial aid from federal sources other than Title IV Programs, such as the programs administered by the U.S. Department of Veterans Affairs and under the Workforce Innovation and Opportunity Act.

We believe that our industry-focused educational model and national presence has enabled us to develop valuable industry relationships, which provide us with significant competitive advantages and supports our market leadership, along with enabling us to provide highly specialized education to our students, resulting in enhanced employment opportunities and the potential for higher wages for our graduates.

Overview of the Three and Six Months Ended March 31, 2024

Student Metrics

UTI Three Months Ended March 31,% 2024 2023 Change Six Months Ended March 31,% 2024 2023(1) Change
Total new student starts 2,840 2,374 19.6% 5,154 4,348 18.5%
Average undergraduate full-time active students 13,810 12,516 10.3% 14,065 13,014 8.1%
End of period undergraduate full-time active students 13,590 12,104 12.3% 13,590 12,104 12.3%
Concorde
Total new student starts 2,640 2,252 17.2% 4,672 2,573 81.6%
Average undergraduate full-time active students 8,506 7,808 8.9% 8,375 7,773 7.7%
End of period undergraduate full-time active students 8,487 7,708 10.1% 8,487 7,708 10.1%
Consolidated
Total new student starts 5,480 4,626 18.5% 9,826 6,921 42.0%
Average undergraduate full-time active students 22,316 20,324 9.8% 22,440 20,787 8.0%
End of period undergraduate full-time active students 22,077 19,812 11.4% 22,077 19,812 11.4%

(1) New student starts and average student data for Concorde presented in the six months ended March 31, 2023 column represents the period of UTI’s ownership, or December 1, 2022 through March 31, 2023.

For three and six months ended March 31, 2024, the increase in UTI new student starts, average undergraduate full-time active students and end of period students was primarily due to the successful rollout of 14 new programs across nine campuses during the fiscal 2023 fourth quarter and fiscal 2024 first quarter, and increased student demand at a majority of the remaining UTI campuses. Concorde rolled out four new programs at three campuses during the same time period, and also rolled out new cash pay “short courses” at a number of campuses. These program rollouts, along with high demand for its existing programs resulted in increases in new student starts, average undergraduate full-time active students and end of period students compared to the prior year.

Our ability to start new students can be influenced by various factors including: impacts of the state of the general macro-economic environment and its impact on price sensitivity and the ability and willingness of students and their families to incur debt to fund their education; unemployment rates; competition; adverse media coverage, legislative, or regulatory actions and investigations by attorneys general and various agencies related to allegations of wrongdoing on the part of other companies within the education and training services industry, which can cast the aggregate “for-profit” education industry in a negative light; and pandemics and or other national, state or local emergencies as declared by various government authorities.

Operations

Revenues for the three months ended March 31, 2024 were $184.2 million, an increase of $20.4 million, or 12.4%, from the comparable period in the prior year. UTI revenues increased by approximately $15.8 million, or 14.7%, and Concorde revenues increased by approximately $4.6 million, or 8.2%. Both segment increases were driven by the higher student starts and average undergraduate full-time active students as previously noted.

Revenues for the six months ended March 31, 2024 were $358.9 million, an increase of $75.0 million, or 26.4%, from the comparable period in the prior year. UTI revenues increased by approximately $25.6 million, or 12.0%, driven primarily by the higher student starts and average undergraduate full-time active students compared to the prior year. Concorde revenues increased by approximately $49.5 million, or 70.0%, primarily due to the inclusion of two extra months of revenue compared to the prior year period, along with higher student starts and average undergraduate full time active students.

Total income from operations was $11.2 million and $25.4 million during the three and six months ended March 31, 2024, respectively, compared to $5.9 million and $10.4 million for the three and six months ended March 31, 2023, respectively.

The increase for the three-month period was primarily driven by the increased revenues from the larger student population. The increase for the six-month period was due to the inclusion of two additional months of revenue for Concorde as compared to the prior year period. Additionally, productivity improvements and proactive cost actions have been a key part of our operating model for the past several years, and we continue to identify and execute on optimization opportunities throughout our operations in both segments.

Business Strategy

Our business strategy has three key tenets: (i) to grow the business by more deeply penetrating existing target markets and adding new markets; (ii) to diversify the business by adding new locations, programs, and offerings that maximize the lifetime value of our students; and (iii) to continually optimize the business by constantly enhancing operational efficiency.

During the six months ended March 31, 2024, we executed the following as part of our business strategy:

  • Concorde announced the launch of additional program offerings in dental hygiene in Jacksonville, Florida and sonography in Orlando, Florida and San Bernardino, California. Two additional dental hygiene programs are planned to launch later in 2024, pending final regulatory approval.
  • UTI announced additional program expansions of Heating Ventilation Air Conditioning and Refrigeration in Avondale, Arizona, Bloomfield, New Jersey, Long Beach, California and Sacramento, California. The programs are expected to launch in late fiscal 2024 and early fiscal 2025.
  • UTI announced plans to consolidate our two Houston, Texas campuses to align the curriculum, student facing systems, and support services to better serve students seeking careers in in-demand fields. As part of the transition, the MIAT Houston campus, acquired in November 2021, will begin operating under the UTI brand and implement a phased teach-out agreement starting in May 2024. Both facilities will remain in use post-consolidation. See Note 15 of the notes to our condensed consolidated financial statements herein for further details on the restructuring.
  • UTI obtained Federal Aviation Administration approval for the Airframe and Powerplant Technician program at the Miramar, Florida campus and started the first cohort of students during the first quarter of 2024, which completed the rollout of the 14 new programs announced in fiscal 2023.
  • UTI announced new partnerships with United Service Organization, Hawaiian Airlines, iRacing, and several other companies for early employment programs. These partnerships will provide additional career transition and placement opportunities for UTI students.

In addition, we continue to pursue other opportunities that align with our business strategy.

Regulatory Environment

See Note 20 of the notes to our condensed consolidated financial statements herein for a discussion of our regulatory environment.

Results of Operations: Three Months Ended March 31, 2024 Compared to Three Months Ended March 31, 2023

The following table sets forth selected statements of operations data as a percentage of revenues for each of the periods indicated.

Three Months Ended March 31, 2024 2023
Revenues 100.0% 100.0%
Operating expenses:
Educational services and facilities 52.9% 53.1%
Selling, general and administrative 41.0% 43.3%
Total operating expenses 93.9% 96.4%
Income from operations 6.1% 3.6%
Interest income 0.8% 1.1%
Interest expense (1.2)% (1.6)%
Other income (expense), net 0.1% 0.1%
Total other expense, net (0.3)% (0.4)%
Income before income taxes 5.7% 3.2%
Income tax expense (1.5)% (1.1)%
Net income 4.2% 2.2%
Preferred stock dividends —% (0.8)%
Income available for distribution 4.2% 1.4%
Income allocated to participating securities —% (0.5)%
Net income available to common shareholders 4.2% 0.9%

Revenues

The following table presents revenue by segment (in thousands):

Three Months Ended March 31, 2024 UTI Concorde Consolidated Three months ended March 31, 2023 UTI Concorde Consolidated
Revenue $123,323 $60,853 $184,176 $107,560 $56,260 $163,820
Year over Year % Change 14.7% 8.2% 12.4%

Revenues for the three months ended March 31, 2024 were $184.2 million, an increase of $20.4 million, or 12.4%, as compared to revenues of $163.8 million for the three months ended March 31, 2023.

UTI

Revenues for UTI for the three months ended March 31, 2024 were $123.3 million compared to $107.6 million in the prior period. Revenue increased primarily due to a 10.3% increase in average undergraduate full-time active students during the quarter and 19.6% increase in new student starts from the prior year.

Concorde

Revenues for Concorde for the three months ended March 31, 2024 were $60.9 million compared to $56.3 million in the prior period. Revenues increased primarily due to an 8.9% increase in average undergraduate full-time active students during the quarter and 17.2% increase in new student starts from the prior year.

Educational services and facilities expenses

Educational services and facilities expenses were $97.5 million for the three months ended March 31, 2024, as compared to $86.9 million for the three months ended March 31, 2023. This increase was primarily due to the increased student volumes during the period and costs associated with our business strategies.

The following tables set forth the significant components of our educational services and facilities expenses by segment (in thousands):

Three Months Ended March 31, 2024 UTI Concorde Consolidated
Salaries, employee benefits and tax expense $30,655 $23,768 $54,423
Bonus expense 746 333 1,079
Stock-based compensation 104 — 104
Compensation and related costs 31,505 24,101 55,606
Occupancy costs 7,586 5,424 13,010
Supplies, maintenance and student expense 8,102 4,351 12,453
Depreciation and amortization expense 5,585 754 6,339
Contract services expense 1,151 526 1,677
Other educational services and facilities expense 6,171 2,232 8,403
Total educational services and facilities expense $60,100 $37,388 $97,488
Three months ended March 31, 2023 UTI Concorde Consolidated
Salaries, employee benefits and tax expense $29,129 $19,696 $48,825
Bonus expense 652 — 652
Stock-based compensation 99 — 99
Compensation and related costs 29,880 19,696 49,576
Occupancy costs 7,944 5,592 13,536
Supplies, maintenance and student expense 5,062 4,104 9,166
Depreciation and amortization expense 4,763 1,530 6,293
Contract services expense 1,012 119 1,131
Other educational services and facilities expense 4,660 2,568 7,228
Total educational services and facilities expense $53,321 $33,609 $86,930

UTI

Compensation and related costs increased by $1.6 million for the three months ended March 31, 2024, primarily due to instructors and other personnel hired to support the additional programs added at the end of fiscal 2023 and in early fiscal 2024.

Supplies, maintenance and student expense increased by $3.0 million primarily due to the increased cost of student housing in support of relocating students.

Other educational services and facilities expense increased by $1.5 million consistent with the increased average undergraduate full-time active students.

Concorde

Compensation and related costs increased by $4.4 million for the three months ended March 31, 2024, primarily due to instructors and other personnel hired to support overall student growth and the launch of additional programs during the current year.

Depreciation expense decreased $0.8 million due to the final adjustments to the purchase price allocation for our acquisition of Concorde as of December 1, 2023, which decreased the depreciable base value of the acquired property and equipment, thereby lowering future depreciation expense.

Selling, general and administrative expenses

Selling, general and administrative expenses for the three months ended March 31, 2024 were $75.5 million, as compared to $70.9 million for the three months ended March 31, 2023. This increase was primarily due to costs associated with our business strategies.

During fiscal 2023, in coordination with the integration of Concorde, we began to reassess our operating model to determine the organizational structure that would best help the Company achieve future growth goals and optimally support the business. Beginning in fiscal 2024, we have executed an internal reorganization to fully transition our operating and reporting model to support a multi-divisional business. As part of the internal reorganization, each of the reportable segments now have dedicated accounting, finance, information technology, and human resources teams. Additionally, human resources and information technology costs that benefit the entire organization are now allocated across UTI, Concorde and Corporate each period based upon relative headcount. As a result, additional costs have moved from Corporate into the UTI segment and to a lesser extent the Concorde segment as resources were redirected to support the segment’s objectives. Due to these changes in allocation methodology, the prior year amounts for selling, general and administrative expenses have been recast for comparability to the current year presentation.

The following tables set forth the significant components of our selling, general and administrative expenses by segment (in thousands):

Three Months Ended March 31, 2024 UTI Concorde Corporate Consolidated
Salaries, employee benefits and tax expense $20,105 $7,173 $3,862 $31,140
Bonus expense 2,677 496 1,128 4,301
Stock-based compensation 209 69 1,972 2,250
Compensation and related costs 22,991 7,738 6,962 37,691
Advertising and marketing expense 13,900 7,040 211 21,151
Professional and contract services expense 1,620 2,232 3,014 6,866
Other selling, general and administrative expenses 6,626 3,209 (47) 9,788
Total selling, general and administrative expenses $45,137 $20,219 $10,140 $75,496
Three months ended March 31, 2023 UTI Concorde Corporate Consolidated
Salaries, employee benefits and tax expense $18,259 $6,807 $3,841 $28,907
Bonus expense 3,339 480 984 4,803
Stock-based compensation 545 — 1,469 2,014
Compensation and related costs 22,143 7,287 6,294 35,724
Advertising and marketing expense 14,179 6,502 — 20,681
Professional and contract services expense 1,906 1,327 3,051 6,284
Other selling, general and administrative expenses 6,223 1,346 683 8,252
Total selling, general and administrative expenses $44,451 $16,462 $10,028 $70,941

31

UTI

Compensation and related costs increased by $0.8 million for the three months ended March 31, 2024 primarily due to additional headcount hired to support the UTI segment and our business strategies.

Advertising and marketing expense remained relatively flat year over year. UTI continues to target cost-efficient marketing with an increased focus on digital media. UTI advertising and marketing expense as a percentage of revenues decreased to 11.3% for the three months ended March 31, 2024 as compared to 13.2% in the prior year.

Concorde

Compensation and related costs increased by $0.5 million for the three months ended March 31, 2024 primarily due to additional headcount hired to support the Concorde segment and our business strategies.

Concorde advertising and marketing increased year over year by $0.5 million. Concorde advertising and marketing expense as a percentage of revenues for the three months ended March 31, 2024 and 2023 remained consistent at 11.6%.

Concorde professional and contract services expenses increased by $0.9 million for the three months ended March 31, 2024 primarily related to the continuing integration activities.

Concorde other selling, general and administrative expenses increased by $1.9 million for the three months ended March 31, 2024 primarily due to an increase of $1.3 million in bad debt expense. The prior year benefited from a favorable adjustment due to aligning accounting policies post acquisition. The allowance for doubtful accounts as a percent of accounts receivable has improved since acquisition.

Corporate

Selling, general and administrative expenses for Corporate increased slightly for the three months ended March 31, 2024 primarily due to a $0.7 million increase in compensation related costs, largely offset by a decrease in other selling, general and administrative expenses.

Income taxes

Income tax expense for the three months ended March 31, 2024 was $2.8 million, or 26.2% of pre-tax income, compared to $1.8 million, or 33.6% of pre-tax income, for the three months ended March 31, 2023. The effective income tax rate for the three months ended March 31, 2024 differed from the federal statutory rate of 21% primarily due to non-deductible executive compensation, federal research and development tax credits and state and local income and franchise taxes. The effective income tax rate for the three months ended March 31, 2023 differed from the federal statutory rate of 21% primarily due to non-deductible executive compensation, transaction costs and state and local income and franchise taxes. See Note 14 of the notes to the condensed consolidated financial statements herein for additional details.

Preferred stock dividends

As of March 31, 2024, no shares of Series A Convertible Preferred Stock, the (“Series A Preferred Stock”) remain outstanding and all rights of the holders to receive future dividends have been terminated due to the combination of the repurchase and conversion of all outstanding preferred shares as of December 18, 2023. See Note 17 of the notes to the condensed consolidated financial statements herein for additional details on the conversion of our Series A Preferred Stock.

Pursuant to the Certificate of Designations of the Series A Preferred Stock (the “CoD”), we recorded a preferred stock cash dividend of $1.3 million for the three months ended March 31, 2023.

Income available for distribution

Income available for distribution refers to net income reduced by dividends on our Series A Preferred Stock. As a result of the foregoing, we reported income available for distribution of $7.8 million and $2.2 million for the three months ended March 31, 2024 and 2023, respectively.

Income allocated to participating securities

Series A Preferred Stock is considered a participating security because, in the event that we pay a dividend or make a distribution on the outstanding common stock, we shall also pay each holder of the Series A Preferred Stock a dividend on an as-converted basis. The two-class method is an earnings allocation formula that determines earnings per share for common stock and participating securities according to dividend and participation rights in undistributed earnings. Under this method, all earnings, distributed and undistributed, are allocated to common shares and participating securities based on their respective rights to receive dividends.

As noted above, no shares of the Series A Preferred Stock remain outstanding and all rights of the holders to receive future dividends have been terminated as of the December 18, 2023 conversion date. As such, there is no income allocated to participating securities for the three months ended March 31, 2024. The income allocated to participating securities for the three months ended March 31, 2023 was $0.8 million.

Net income available to common shareholders

We had $7.8 million and $1.4 million of net income available to common shareholders for the three months ended March 31, 2024 and 2023, respectively.

Results of Operations: Six Months Ended March 31, 2024 Compared to Six Months Ended March 31, 2023

The following table sets forth selected statements of operations data as a percentage of revenues for each of the periods indicated.

Six Months Ended March 31, 2024 2023
Revenues 100.0% 100.0%
Operating expenses:
Educational services and facilities 52.9% 52.3%
Selling, general and administrative 40.0% 44.1%
Total operating expenses 92.9% 96.4%
Income from operations 7.1% 3.6%
Interest income 0.9% 0.9%
Interest expense (1.4)% (1.4)%
Other income (expense), net 0.1% 0.2%
Total other (expense), net (0.4)% (0.3)%
Income before income taxes 6.7% 3.3%
Income tax expense (1.7)% (1.2)%
Net income 5.1% 2.1%
Preferred stock dividends (0.3)% (0.9)%
Income available for distribution 4.8% 1.3%
Income allocated to participating securities (0.8)% (0.5)%
Net income available to common shareholders 4.0% 0.8%

33

Revenues

The following table presents revenue by segment (in thousands):

Six Months Ended March 31, 2024 UTI Concorde Consolidated Six Months Ended March 31, 2023 UTI Concorde Consolidated
Revenue $238,697 $120,174 $358,871 $213,133 $70,691 $283,824
Year over Year % Change 12.0% 70.0% 26.4%

Revenues for the six months ended March 31, 2024 were $358.9 million, an increase of $75.0 million, or 26.4%, as compared to revenues of $283.8 million for the six months ended March 31, 2023.

UTI

Revenues for UTI for the six months ended March 31, 2024 were $238.7 million compared to $213.1 million in the prior year period. Revenue increased primarily due to an overall increase in average revenue per student and an 8.1% increase in overall average undergraduate full-time active students.

Concorde

Revenues for Concorde for the six months ended March 31, 2024 were $120.2 million compared to $70.7 million in the prior year period. The primary drivers of the increase for Concorde were the inclusion of two additional months of revenue during the current year and an increase in overall average undergraduate full-time active students. Concorde programs are offered year-round, however, there can be fluctuations in the student population due to the timing and size of class starts which are dictated by the accrediting bodies governing the clinical and core programs.

Educational services and facilities expenses

Educational services and facilities expenses were $189.9 million for the six months ended March 31, 2024, as compared to $148.3 million for the six months ended March 31, 2023, which is primarily due to the increase in student volumes during the current period and the inclusion of Concorde results for two additional months in the current year.

The following table sets forth the significant components of our educational services and facilities expenses by segment (in thousands):

Six Months Ended March 31, 2024 UTI Concorde Consolidated
Salaries, employee benefit and tax expenses $57,558 $45,594 $103,152
Bonus expense 1,399 470 1,869
Stock-based compensation 191 — 191
Compensation and related costs 59,148 46,064 105,212
Occupancy costs 15,044 10,987 26,031
Depreciation and amortization expense 10,977 2,012 12,989
Supplies and maintenance and student expense 18,515 8,212 26,727
Contract services expense 2,035 1,029 3,064
Other educational services and facilities expense 11,749 4,125 15,874
Total educational services and facilities expense $117,468 $72,429 $189,897
Six Months Ended March 31, 2023 UTI Concorde Consolidated
Salaries, employee benefit and tax expenses $55,981 $26,255 $82,236
Bonus expense 1,308 — 1,308
Stock-based compensation 180 — 180
Compensation and related costs 57,469 26,255 83,724
Occupancy costs 15,626 7,356 22,982
Depreciation and amortization expense 9,180 1,950 11,130
Supplies, maintenance and student expense 9,647 5,015 14,662
Contract services expense 2,077 175 2,252
Other educational services and facilities expense 10,199 3,389 13,588
Total educational services and facilities expense $104,198 $44,140 $148,338

UTI

Compensation and related costs increased by $1.7 million for the six months ended March 31, 2024 primarily due to instructors and other personnel hired to support the additional programs added at the end of fiscal 2023 and in early fiscal 2024.

Occupancy costs decreased by $0.6 million for the six months ended March 31, 2024 due to the purchase of the three primary buildings at the Orlando, Florida campus in March 2023.

Depreciation and amortization expense increased by $1.8 million for the six months ended March 31, 2024 primarily due to the purchase of the three primary buildings at the Orlando, Florida campus in March 2023 and increased capital expenditures related to the new program launches.

Supplies, maintenance and student expense increased by $8.9 million primarily due to the increased cost of student housing in support of relocating students.

Concorde

Compensation and related costs increased by $19.8 million for the six months ended March 31, 2024 primarily due to the inclusion of two additional months of expenses in the current year in addition to increased instructors and other personnel hired to support the new program expansions.

The other expense increases for the six months ended March 31, 2024 were all primarily driven by the additional two months of activity included in the current year.

Selling, general and administrative expenses

Selling, general and administrative expenses for the six months ended March 31, 2024 were $143.6 million. This represents an increase of $18.5 million, as compared to $125.1 million for the six months ended March 31, 2023, which is primarily due to the inclusion of two additional months of results for Concorde in the current year and costs associated with our growth and diversification strategy.

As previously noted in the results of operations for the comparable three-month periods, the prior year amounts for selling, general and administrative expenses have been recast for comparability to the current year presentation.

The following table sets forth the significant components of our selling, general and administrative expenses by segment (in thousands):

Six Months Ended March 31, 2024 UTI Concorde Corporate Consolidated
Salaries, employee benefit and tax expense $38,571 $13,539 $7,425 $59,535
Bonus expense 5,518 1,216 2,150 8,884
Stock-based compensation 592 77 2,975 3,644
Compensation and related costs 44,681 14,832 12,550 72,063
Advertising and marketing expense 27,253 13,132 211 40,596
Professional and Contract services expense 3,323 3,599 5,521 12,443
Other selling, general and administrative expenses 12,796 5,808 (155) 18,449
Total selling, general and administrative expenses $88,053 $37,371 $18,127 $143,551
Six Months Ended March 31, 2023 UTI Concorde Corporate Consolidated
Salaries, employee benefit and tax expense $34,890 $8,724 $7,715 $51,329
Bonus expense 6,226 668 2,118 9,012
Stock-based compensation 716 — 2,386 3,102
Compensation and related costs 41,832 9,392 12,219 63,443
Advertising and marketing expense 27,528 7,782 — 35,310
Professional and Contract services expense 3,906 1,845 5,226 10,977
Other selling, general and administrative expenses 12,459 2,069 831 15,359
Total selling, general and administrative expenses $85,725 $21,088 $18,276 $125,089

UTI

Compensation and related costs increased by $2.8 million for the six months ended March 31, 2024 primarily due to an increase in headcount to support the UTI segment and our growth and diversification initiatives as compared to the prior year.

Advertising and marketing expense decreased by $0.3 million for the six months ended March 31, 2024, primarily due to timing of spend along with incremental investment to support our growth objectives. We continue to target cost-efficient marketing with an increased focus on digital media. Advertising and marketing expense as a percentage of revenues decreased to 11.4% for the six months ended March 31, 2024 as compared to 12.9% in the prior year.

Concorde

Concorde compensation and related costs increased by $5.4 million for the six months ended March 31, 2024 primarily due to the inclusion of two additional months of expense in the current year and an increase in headcount to support the Concorde segment and our growth and diversification initiatives as compared to the prior year period.

Advertising and marketing expense as a percentage of revenues remained consistent at 10.9% for the six months ended March 31, 2024 as compared to 11.0% in the prior year period.

Selling, general and administrative expenses for Concorde for the six months ended March 31, 2024 increased across all line items as the current year period includes two additional months of expenses compared to the prior year. This increase is also partially due to our continuing integration efforts.

Corporate

Selling, general and administrative expenses for Corporate remained consistent, decreasing by $0.1 million for the six months ended March 31, 2024, with both periods including one-time integration costs related to the Concorde acquisition and costs associated with our growth and diversification strategy.

Income taxes

Our income tax expense for the six months ended March 31, 2024 was $5.9 million, or 24.6% of pre-tax income, compared to income tax expense of $3.3 million, or 34.9% of pre-tax income, for the six months ended March 31, 2023. The effective income tax rate for the six months ended March 31, 2024 differed from the federal statutory rate of 21% primarily due to non-deductible executive compensation, federal research and development tax credits and state and local income and franchise taxes. The effective income tax rate for the six months ended March 31, 2023 differed from the federal statutory rate of 21% primarily due to non-deductible executive compensation, transaction costs and state and local income and franchise taxes. See Note 14 of the notes to the condensed consolidated financial statements herein for additional details.

Preferred stock dividends

As of March 31, 2024, no shares of the Series A Preferred Stock remain outstanding and all rights of the holders to receive future dividends have been terminated due to the combination of the repurchase and conversion of all outstanding preferred shares as of December 18, 2023. See Note 17 of the notes to the condensed consolidated financial statements herein for additional details on the conversion of our Series A Preferred Stock.

Pursuant to the CoD, we recorded a preferred stock cash dividend of $1.1 million and $2.5 million for the six months ended March 31, 2024 and 2023, respectively.

Income available for distribution

Income available for distribution refers to net income reduced by dividends on our Series A Preferred Stock. As a result of the foregoing, we reported income available for distribution of $17.1 million and $3.6 million for the six months ended March 31, 2024 and 2023, respectively.

Income allocated to participating securities

Series A Preferred Stock is considered a participating security because, in the event that we pay a dividend or make a distribution on the outstanding common stock, we shall also pay each holder of the Series A Preferred Stock a dividend on an as-converted basis. The two-class method is an earnings allocation formula that determines earnings per share for common stock and participating securities according to dividend and participation rights in undistributed earnings. Under this method, all earnings, distributed and undistributed, are allocated to common shares and participating securities based on their respective rights to receive dividends.

As noted above, no shares of the Series A Preferred Stock remain outstanding and all rights of the holders to receive future dividends have been terminated as of the December 18, 2023 conversion date. The amount of income allocated to the participating securities for the six months ended March 31, 2024 and 2023 was $2.9 million and $1.3 million, respectively.

Net income available to common shareholders

After allocating the income to the participating securities, we had $14.2 million and $2.3 million of net income available to common shareholders for the six months ended March 31, 2024 and 2023, respectively.

Non-GAAP Financial Measures

Our earnings before interest income, income taxes, depreciation and amortization (“EBITDA”) for the three and six months ended March 31, 2024 were $18.5 million and $39.9 million, respectively, compared to $12.8 million and $22.8 million for the three and six months ended March 31, 2023, respectively. We define EBITDA as net income, before interest (income) expense, income tax expense (benefit), and depreciation and amortization.

EBITDA is a non-GAAP financial measure which is provided to supplement, but not substitute for, the most directly comparable GAAP measure. We choose to disclose this non-GAAP financial measure because it provides an additional analytical tool to clarify our results from operations and helps to identify underlying trends. Additionally, this measure helps compare our performance on a consistent basis across time periods. Management also utilizes EBITDA as a performance measure internally. To obtain a complete understanding of our performance, this measure should be examined in connection with net income determined in accordance with GAAP. Since the items excluded from this measure should be examined in connection with net income in determining financial performance under GAAP, this measure should not be considered an alternative to net income as a measure of our operating performance or profitability. Exclusion of items in our non-GAAP presentation should not be construed as an inference that these items are unusual, infrequent or non-recurring. Other companies, including other companies in the education industry, may calculate EBITDA differently than we do, limiting its usefulness as a comparative measure across companies. Investors are encouraged to use GAAP measures when evaluating our financial performance.

EBITDA reconciles to net income, as follows (in thousands):

Three Months Ended March 31, 2024 2023 Six Months Ended March 31, 2024 2023
Net income $7,787 $3,480 $18,176 $6,128
Interest income (1,427) (1,805) (3,402) (2,628)
Interest expense 2,184 2,637 5,055 4,060
Income tax expense 2,767 1,763 5,927 3,288
Depreciation and amortization 7,202 6,746 14,186 11,994
EBITDA $18,513 $12,821 $39,942 $22,842

Liquidity and Capital Resources

Overview of Liquidity

Based on past performance and current expectations, we believe that our cash flows from operations, cash on hand and investments, and revolving credit facility will satisfy our working capital needs, capital expenditures, commitments and other liquidity requirements associated with our existing operations, as well as announced program expansions over the next 12 months and beyond. Our cash position is available to fund strategic long-term growth initiatives, including opening additional campuses in new markets and the creation and expansion of new programs in existing markets where we continue to optimize utilization of our campus facilities.

Our aggregate cash and cash equivalents were $116.1 million as of March 31, 2024, a decrease of $35.4 million from September 30, 2023 due primarily to net repayments of $19.0 million to the revolving credit facility and the $11.3 million used to repurchase our Series A preferred shares. We also had available liquidity under our revolving credit facility of $29.0 million as of March 31, 2024.

Strategic Uses of Cash

We believe that additional strategic uses of our cash resources may include consideration of additional strategic acquisitions and organic growth initiatives, the purchase of real estate assets, subsidizing funding alternatives for our students, and the repurchase of common stock, among others. To the extent that potential acquisitions are large enough to require financing beyond cash from operations, cash and cash equivalents, and short-term investments, or we need capital to fund operations, new campus openings or expansion of programs at existing campuses, we may enter into additional credit facilities, issue debt or issue additional equity.

Long-term Debt

As of March 31, 2024, we had $142.3 million of long-term debt outstanding, which is comprised of two term loans, a finance lease and a revolving credit facility. Of the $142.3 million outstanding, $28.8 million relates to a term loan that bears interest at the rate of Term SOFR plus 2.0% and a tranche rate adjustment of 0.046% over the seven-year term secured in connection with the Avondale, Arizona campus property purchased in December 2020. Approximately $37.3 million relates to a term loan that bears interest at the rate of Term SOFR plus 2.0% over the seven-year term, secured in connection with the Lisle, Illinois campus property. For each of the term loans, a derivative interest rate swap is in place that fixes the interest rate on

50% of the loan at a market rate at the time the derivative was initiated. Approximately $5.2 million relates to a finance lease for a campus within our Concorde segment. The remaining $71.0 million relates to funds drawn from the $100.0 million revolving credit facility that was secured in connection with the Concorde acquisition. See Note 12 of the notes to the condensed consolidated financial statements herein for additional details on the term loans and the revolving credit facility.

Dividends

We currently do not pay a cash dividend on our common stock. A final cash dividend payment of $1.1 million was paid to Series A Preferred Stock holders of record as of December 18, 2023 during the three months ended December 31, 2023 as a result of the conversion of the Series A Preferred Stock. See Note 17 of the notes to the condensed consolidated financial statements herein for additional details on the conversion of our preferred stock.

Principal Sources of Liquidity

Our principal source of liquidity is operating cash flows and existing cash and cash equivalents. A majority of our revenues are derived from Title IV Programs and various veterans’ benefits programs. Federal regulations dictate the timing of disbursements of funds under Title IV Programs. Students must apply for new funding for each academic year consisting of 30-week periods. Loan funds are generally provided in two disbursements for each academic year. The first disbursement for first-time borrowers is usually received 30 days after the start of a student’s academic year, and the second disbursement is typically received at the beginning of the 16th week from the start of the student’s academic year. Under our UTI proprietary loan program, we bear all credit and collection risk and students are not required to begin repayment until six months after the student completes or withdraws from his or her program. Similarly, we bear all credit and collection risk for students paying through UTI cash payment plans and those under a retail installment contract at Concorde. These factors, together with the timing of when our students begin their programs, affect the timing and seasonality of our operating cash flow.

Operating Activities

Our net cash provided by operating activities was $8.3 million for the six months ended March 31, 2024, compared to net cash used of $4.3 million for the six months ended March 31, 2023.

Net income, after adjustments for non-cash items, for the six months ended March 31, 2024 provided cash of $50.5 million. The non-cash items included $14.2 million for depreciation and amortization expense, $11.0 million for amortization of right-of-use assets for operating leases, $3.8 million for stock-based compensation expense, and $3.2 million for bad debt expense.

Changes in operating assets and liabilities used cash of $42.2 million primarily due to the following:

  • The change in deferred revenue used cash of $18.1 million and was primarily attributable to the timing of student starts, the number of students in school and where they were at period end in relation to completion of their program at March 31, 2024 as compared to September 30, 2023.
  • Changes in our operating lease liability, primarily as a result of rent payments, used cash of $10.1 million.
  • The increase in prepaid expenses used cash of $4.5 million primarily due to the timing of payments.
  • The increase in notes receivable used cash of $4.4 million primarily due to higher utilization of the Tuition Loan Program.

Net income, after adjustments for non-cash items, for the six months ended March 31, 2023 provided cash of $35.2 million. The non-cash items included $12.0 million for depreciation and amortization expense, $10.1 million for amortization of right-of-use assets for operating leases, $3.3 million for stock-based compensation expense, $2.5 million related to changes in deferred tax assets, and $2.1 million for bad debt expense.

Changes in operating assets and liabilities used cash of $39.5 million primarily due to the following:

  • The decrease in accounts payable and accrued expenses used cash of $16.4 million primarily related to the timing of payments to vendors and for payroll and bonus accruals.
  • Changes in our operating lease liability, primarily as a result of rent payments, used cash of $10.7 million.
  • The change in deferred revenue when excluding the initial purchase price allocation for Concorde used cash of $9.6 million and was primarily attributable to the timing of student starts, the number of students in school and where they were at period end in relation to completion of their program at March 31, 2023 as compared to September 30, 2022.
  • The change in receivables when excluding the initial purchase price allocation for Concorde used cash of $3.9 million and was primarily due to the timing of Title IV disbursements and other cash receipts on behalf of our students.
  • The change in other assets provided cash of $2.7 million primarily due to activity related to the long-term portion of Concorde’s retail installment contracts.

Investing Activities

During the six months ended March 31, 2024, cash used in investing activities was $9.8 million for the purchase of property and equipment to support new program expansion at both UTI and Concorde.

During the six months ended March 31, 2023, cash used in investing activities was $26.6 million. The cash outflow was primarily related to the purchase of property and equipment of $38.6 million. During the six months ended March 31, 2023, we purchased three buildings and the associated land at our Orlando, Florida campus for $26.2 million, including closing costs and other fees. Additionally, we had continued capital expenditures for further construction at the UTI Austin, Texas and Miramar, Florida campuses, in addition to program expansion costs for both UTI and Concorde. Further, on December 1, 2022, we completed the acquisition of Concorde which resulted in $17.0 million of cash paid for acquisitions, net of cash acquired. Partially offsetting the cash outflows, is the $29.0 million in proceeds from maturities of held-to-maturity securities.

Financing Activities

During the six months ended March 31, 2024, cash used in financing activities was $35.0 million which was primarily related to $19.0 million in net payments on the revolving credit facility, or $39.0 million in payments offset by $20.0 million in proceeds. Additionally, $11.5 million was used to repurchase of Series A Preferred Stock. See Note 17 of the notes to the condensed consolidated financial statements herein for additional details on the repurchase. Other uses of cash included payroll taxes paid for stock-based compensation through shares withheld of $2.1 million, the payment of long-term debt of $1.2 million, and the payment of preferred dividends of $1.1 million.

During the six months ended March 31, 2023, cash provided by financing activities was $85.5 million which was primarily related to proceeds from our revolving credit facility of $90.0 million, partially offset by the semi-annual payment of preferred stock dividends of $2.5 million, $0.7 million in payroll taxes paid for stock-based compensation through shares withheld, payment of long-term debt of $0.7 million, and debt issuance costs related to the revolving credit facility of $0.5 million

Seasonality and Trends

Our operating results normally fluctuate as a result of seasonal variations in our business, principally due to changes in total student population and costs associated with opening or expanding our campuses. Our student population varies as a result of new student enrollments, graduations and student attrition. Historically, UTI has had lower student populations in the third quarter than in the remainder of the year because fewer students are enrolled during the summer months. Additionally, UTI has had higher student populations in the fourth quarter than in the remainder of the year because more students enroll during this period. Concorde typically has higher student populations in January and August through October for its core programs and in February for its clinical programs. UTI and Concorde core program expenses do not vary significantly with changes in student population and revenues. Concorde clinical program expenses fluctuate based on the academic calendar and season due to the timing of clinical starts. We expect quarterly fluctuations in operating results to continue as a result of seasonal enrollment patterns. However, such patterns may change as a result of new school openings, new program introductions, increased enrollments of adult students or acquisitions.

Critical Accounting Policies and Estimates

The preparation of financial statements and related disclosures in conformity with GAAP and management’s discussion and analysis of our financial condition and operating results require management to make judgments, assumptions and estimates that affect the amounts reported. There were no significant changes in our critical accounting policies and estimates in the six months ended March 31, 2024 from those previously disclosed in Part II, Item 7 of our 2023 Annual Report on Form 10-K.

Recent Accounting Pronouncements

For information regarding recent accounting pronouncements, see Note 3 of the notes to the condensed consolidated financial statements herein.

Market risk

As filed, 299 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

There have been no other material changes in our market risk exposure during the six months ended March 31, 2024. For a discussion of our exposure to market risk, refer to Part II Item 7A. “Quantitative and Qualitative Disclosures About Market Risk” contained in our 2023 Annual Report on Form 10-K.

Controls and procedures

As filed, 3,261 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Evaluation of Disclosure Controls and Procedures

Under the supervision and with the participation of our management, including our Chief Executive Officer and our Chief Financial Officer, we have evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act), pursuant to Exchange Act Rule 13a-15 as of the end of the period covered by this report. Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective as of March 31, 2024 to provide reasonable assurance that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is (i) recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms and (ii) accumulated and communicated to our management, including our principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

Changes in Internal Control Over Financial Reporting

There were no changes in our internal control over financial reporting identified in connection with the evaluation required by Exchange Act Rule 13a-15(d) or 15d-15(d) that occurred during the three months ended March 31, 2024 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Limitations on Effectiveness of Controls and Procedures

Our management, including our Chief Executive Officer and our Chief Financial Officer, does not expect that our disclosure controls and procedures or our internal controls over financial reporting will prevent all error and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues, misstatements, errors and instances of fraud, if any, within our company have been or will be prevented or detected. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of simple error or mistake. Controls also can be circumvented by the individual acts of some persons, by collusion of two or more people or by management override of the controls. The design of any system of controls is based in part on certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Projections of any evaluation of controls effectiveness to future periods are subject to risks that internal controls may become inadequate as a result of changes in conditions, or through the deterioration of the degree of compliance with policies or procedures.

Risk factors

As filed, 667 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

In addition to the other information set forth in this Quarterly Report on Form 10-Q, including the information contained in Part I, Item 3, you should carefully consider the factors discussed in Part I, Item IA of our 2023 Annual Report on Form 10-K, which could materially affect our business, financial condition or operating results. The risks described in this Quarterly Report on Form 10-Q and in our 2023 Annual Report on Form 10-K are not the only risks we face. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition or operating results.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2024-03-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2024-01-01 to 2024-03-31$184.2mus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Revenue6 months2023-10-01 to 2024-03-31$358.9mus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Selling, general and administrative3 months2024-01-01 to 2024-03-31$75.5mus-gaap:SellingGeneralAndAdministrativeExpense
Selling, general and administrative6 months2023-10-01 to 2024-03-31$143.6mus-gaap:SellingGeneralAndAdministrativeExpense
Operating income3 months2024-01-01 to 2024-03-31$11.2mus-gaap:OperatingIncomeLoss
Operating income6 months2023-10-01 to 2024-03-31$25.4mus-gaap:OperatingIncomeLoss
Interest expense3 months2024-01-01 to 2024-03-31$2.2mus-gaap:InterestExpense
Interest expense6 months2023-10-01 to 2024-03-31$5.1mus-gaap:InterestExpense
Income tax3 months2024-01-01 to 2024-03-31$2.8mus-gaap:IncomeTaxExpenseBenefit
Income tax6 months2023-10-01 to 2024-03-31$5.9mus-gaap:IncomeTaxExpenseBenefit
Net income3 months2024-01-01 to 2024-03-31$7.8mus-gaap:NetIncomeLoss
Net income6 months2023-10-01 to 2024-03-31$18.2mus-gaap:NetIncomeLoss
Diluted EPS3 months2024-01-01 to 2024-03-31$0.14us-gaap:EarningsPerShareDiluted
Diluted EPS6 months2023-10-01 to 2024-03-31$0.31us-gaap:EarningsPerShareDiluted
Basic EPS3 months2024-01-01 to 2024-03-31$0.14us-gaap:EarningsPerShareBasic
Basic EPS6 months2023-10-01 to 2024-03-31$0.32us-gaap:EarningsPerShareBasic
Diluted shares (weighted)3 months2024-01-01 to 2024-03-3154,770,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Diluted shares (weighted)6 months2023-10-01 to 2024-03-3146,050,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow6 months2023-10-01 to 2024-03-31$8.3mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure6 months2023-10-01 to 2024-03-31$9.8mus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2024-03-31$116.1mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2024-03-31$170.2mus-gaap:AssetsCurrent
Total assetsAt period end2024-03-31$702.1mus-gaap:Assets
Current liabilitiesAt period end2024-03-31$166.4mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2024-03-31$469.5mus-gaap:Liabilities
Long-term debtAt period end2024-03-31$139.3mus-gaap:LongTermDebtNoncurrent
Current portion of debtAt period end2024-03-31$2.6mus-gaap:LongTermDebtCurrent
Shareholders' equityAt period end2024-03-31$232.6mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001261654-24-000045. Last ingested by Listed: Nov 14, 2026, 12:25 ET. Listed shows no prices and gives no investment advice.